Abstract:Synthetic short interfering RNA (siRNA) oligonucleotides can trigger the RNA interference pathway and lead to selective gene silencing. Despite considerable enthusiasm and investment, formidable challenges remain that may deter translating this breakthrough discovery into clinical applications. In particular, the development of efficient, nontoxic, nonimmunogenic methods for delivering siRNA in vivo has proven to be exceptionally challenging. Thorough analysis of the relationship between the structure and function of siRNA carrier systems, both in isolation and in complex with RNA, will facilitate the design of efficient nonviral siRNA delivery vehicles. In this study, we explore the relationship between the physicochemical characteristics and the biological activity of "lipitoid" compounds as potent siRNA delivery vehicles. Lipitoids are cationic peptidomimetic oligomers incorporating a peptoid and a phospholipid moiety. Lipitoids can associate with siRNA oligonucleotides and self-assemble into spherical lipitoid-based nanoparticles (LNPs), with dimensions that are dependent upon the medium and the stoichiometric ratio between the cationic monomers of the lipitoid and anionic siRNA oligonucleotides. The morphology, gene silencing efficiency, and cytotoxicity of the siRNA-loaded LNPs are similarly sensitive to the stoichiometry of the complexes. The medium in which the LNPs are formed affects the assembled cargo particles' characteristics such as particle size, transfection efficiency, and stability. Formation of the LNPs in the biological, serum-free medium OptiMEM resulted in LNPs an order of magnitude larger than LNPs formed in water, and were twice as efficient in siRNA transfection compared to LNPs formed in water. Inhibitor studies were conducted to elucidate the efficiency of lysosomal escape and the uptake mechanism of the siRNA-loaded LNPs. Our results suggest that these lipitoid-based, siRNA-loaded spherical LNPs are internalized through a lipid raft-dependent and dynamin-mediated pathway, circumventing endosomal and lysosomal encapsulation. The lipitoid-siRNA nanospheres proved to be suitable platforms for investigating the critical parameters determining the efficiency of transfection agents, revealing the necessity for conducting characterization studies in biological media. The investigation of the LNP internalization pathway points to an alternative uptake route that bypasses the lysosome, explaining the surprisingly high efficiency of LNPs and suggesting that the uptake mechanism should be probed rather than assumed for the next generation of rationally designed transfection agents.

Inter-molecular β-sheet structure facilitates lung-targeting siRNA delivery

Shear-responsive peptide/siRNA complexes as lung-targeting gene vectors

Fullerene-based nanocomplex assists pulmonary delivery of siRNA for treating metastatic lung cancer

A pH sensitive co-delivery system of siRNA and doxorubicin for pulmonary administration to B16F10 metastatic lung cancer

A Nanoplatform Self-Assembled by Coordination Delivers Sirna for Lung Cancer Therapy

Efficient Systemic Delivery Of Sirna By Using High-Density Lipoprotein-Mimicking Peptide Lipid Nanoparticles

Optimizing the Size of Micellar Nanoparticles for Efficient Sirna Delivery

Delivery Pathway Regulation of 3′,3″-Bis-peptide-sirna Conjugate Via Nanocarrier Architecture Engineering

Lung-specific supramolecular nanoparticles for efficient delivery of therapeutic proteins and genome editing nucleases

Nanometer-scale siRNA carriers incorporating peptidomimetic oligomers: physical characterization and biological activity

Biodistribution of Therapeutic Small Interfering RNAs Delivered with Lipid-Substituted Polyethylenimine-Based Delivery Systems

A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids

Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery

Chemical Modification and Delivery System of Small Interfering RNA Drugs

Zwitterionic Polymer Lipid Nanoparticles Enabling Selective Organ Targeting Delivery of Small Interfering RNA for the Treatment of Hepatic and Pulmonary Inflammation

Porous Silicon Microparticles for Delivery of Sirna Therapeutics

Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome

Rod-shaped polypeptide nanoparticles for siRNA delivery

Co-delivery of PD-L1- and EGFR-targeting siRNAs by synthetic PEG 12 -KL4 peptide to the lungs as potential strategy against non-small cell lung cancer

Systemic Administration of Sirna Via Crgd-Containing Peptide

Binary and Ternary Complexes Based on Polycaprolactone-Graft-Poly (N, N-Dimethylaminoethyl Methacrylate) for Targeted Sirna Delivery